Abstract
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transforming the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2- advanced breast cancer. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+ breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 4 / metabolism
-
Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 6 / metabolism
-
Female
-
Humans
-
Molecular Targeted Therapy
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptor, ErbB-2 / metabolism*
-
Receptors, Estrogen / metabolism*
-
Receptors, Progesterone / metabolism*
-
Signal Transduction / drug effects
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Receptors, Estrogen
-
Receptors, Progesterone
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
CDK4 protein, human
-
CDK6 protein, human
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase 6